PANTHERx Rare announced that it has been selected by Aadi Bioscience (Aadi) as the exclusive U.S. pharmacy distribution partner for new drug FYARRO™ (sirolimus protein-bound particles for injectable suspension) (albumin-bound).
Aadi is a commercial-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi’s primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site.
PANTHERx Rare is one of the largest and fastest growing rare pharmacies in the United States. PANTHERx transforms lives by delivering medicine breakthroughs, clinical excellence, and access solutions to people living with rare and devastating conditions.
Aadi’s lead product is FYARRO™ (sirolimus albumin-bound nanoparticles for injectable suspension; nab-sirolimus; ABI-009), an mTOR inhibitor bound to human albumin that has demonstrated significantly higher tumor accumulation, greater mTOR target suppression, and increased tumor growth inhibition over other mTOR inhibitors in preclinical models.
FYARRO is an mTOR inhibitor indicated for the treatment of adult patients with locally advanced unresectable or metastatic perivascular epithelioid cell tumor (PEComa).
Aadi is focused on the commercialization of the now FDA-approved FYARRO™ as the only product indicated for locally advanced unresectable or metastatic malignant PEComa during the first quarter of 2022. Aadi plans to have the company be the recognized leader in precision oncology by establishing FYARRO™ as a standard of care for malignant PEComa for leading cancer centers.
PANTHERx supports rare disease patients across the country, addressing the unique needs of every patient and assisting with their personal journeys. Communications and support services are tailored to the desires of each patient and the requirements of their life-changing medications.
Takeaway: PantheRx Rare’s selection as the exclusive distributor of drugs to treat rare diseases continues to be recognized by pharmaceutical manufacturers